To target ERα and the “endogenous” estrogen signaling pathway, as opposed to high exogenous estrogen doses, many drugs are currently available to inhibit the action of this receptor in the context of ERα-positive breast cancer (23), namely selective estrogen receptor modulators (SERMs). Here, ESR1 is linked to breast carcinoma.